Academic Journal
Safety of Coadministration of Continuous Infusions of Propofol and Clevidipine: A Multi-Site Retrospective Analysis.
| Τίτλος: | Safety of Coadministration of Continuous Infusions of Propofol and Clevidipine: A Multi-Site Retrospective Analysis. |
|---|---|
| Συγγραφείς: | Warfield MN; Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA., Cole KC; Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, USA., Heybati K; Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA., Vollmer NJ; Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA., Wieruszewski ED; Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.; Department of Emergency Medicine, Mayo Clinic, Rochester, Minnesota, USA., Yadav H; Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA., Rabinstein AA; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA., Brown CS; Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.; Department of Emergency Medicine, Mayo Clinic, Rochester, Minnesota, USA. |
| Πηγή: | Pharmacotherapy [Pharmacotherapy] 2026 Sep; Vol. 46 (9), pp. e70196. |
| Τύπος έκδοσης: | Journal Article; Multicenter Study |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 8111305 Publication Model: Print Cited Medium: Internet ISSN: 1875-9114 (Electronic) Linking ISSN: 02770008 NLM ISO Abbreviation: Pharmacotherapy Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2012- : Malden, MA : Wiley-Blackwell Original Publication: [Carlisle, MA : Pharmacotherapy Publications, c1981- |
| Ιατρικοί όροι (MeSH): | Propofol*/administration & dosage , Propofol*/adverse effects , Pancreatitis*/chemically induced , Pancreatitis*/epidemiology , Hypertriglyceridemia*/chemically induced , Hypertriglyceridemia*/epidemiology , Pyridines*/administration & dosage , Pyridines*/adverse effects, Triglycerides/blood ; Retrospective Studies ; Humans ; Male ; Female ; Risk Factors ; Middle Aged ; Infusions, Intravenous ; Aged |
| Περίληψη: | Introduction: Patients often receive propofol for sedation and clevidipine for hypertension in the intensive care unit. Both agents are formulated as a lipid emulsion, which may increase the risk of hypertriglyceridemia and acute pancreatitis with their coadministration. We aimed to determine the incidence of hypertriglyceridemia and acute pancreatitis with concurrent administration of propofol and clevidipine and identify patient risk factors for hypertriglyceridemia. Methods: This was a multicenter retrospective study of adult patients (≥ 18 years old) receiving concurrent propofol and clevidipine infusions for ≥ 6 h. The primary outcome was the frequency of triglyceride levels greater than 400 mg/dL and acute pancreatitis. The secondary outcome was risk factors associated with hypertriglyceridemia during concurrent propofol and clevidipine infusions until both infusions had been discontinued. Univariable and multivariable logistic regression analyses were used to assess risk factors of hypertriglyceridemia in patients receiving concurrent propofol and clevidipine infusions. Results: Across 1,226 patients, the median duration of infusion overlap was 12.4 [interquartile range (IQR) 8.3, 22.7] hours. The mean age of the cohort was 59.6 [standard deviation (SD) 14.9] years, and 59.4% were male. Assuming those without a triglyceride level drawn did not have hypertriglyceridemia, hypertriglyceridemia after initiation of propofol and clevidipine infusion was found in 7.7% [95% confidence interval (CI) 6.3% to 9.3%] of the entire cohort. Twenty-six patients (2.1%) had a diagnosis of pancreatitis after initiation of lipid infusions, of which 12 cases were possibly infusion-related, and one case was likely infusion-related. After calculating the Naranjo Scale, all 13 cases of pancreatitis were possibly related to propofol or clevidipine infusions. Based on a multivariable logistic regression of those with a triglyceride level available, risk factors for hypertriglyceridemia included pancreatitis within the past 5 years [adjusted odds ratio (aOR) 2.77, 95% CI, 1.23 to 6.23] and statin use (aOR 1.94, 95% CI, 1.13 to 3.34). Conclusions: In our cohort of patients receiving concurrent propofol and clevidipine, the frequency of hypertriglyceridemia and acute pancreatitis was low. Further comparative studies are warranted to assess the risk of pancreatitis with the addition of clevidipine to propofol. (© 2026 ACCP Foundation, Ltd.) |
| References: | Lancet. 2007 Oct 20;370(9596):1453-7. (PMID: 18064739) Crit Care Explor. 2020 Dec 16;2(12):e0303. (PMID: 33354676) Pharmacotherapy. 2026 Sep;46(9):e70196. (PMID: 42666011) Ann Am Thorac Soc. 2025 Feb;22(2):235-246. (PMID: 39393346) Acta Paediatr. 1995 Sep;84(9):1060-4. (PMID: 8652960) Cureus. 2018 Aug 20;10(8):e3165. (PMID: 30357028) Nutrition. 1992 May-Jun;8(3):155-60. (PMID: 1525430) Ann Pharmacother. 2024 Dec;58(12):1187-1192. (PMID: 38407124) Ann Am Thorac Soc. 2023 Jan;20(1):94-101. (PMID: 36053664) Clin Pharmacol Ther. 1981 Aug;30(2):239-45. (PMID: 7249508) Crit Care Explor. 2020 Nov 30;2(12):e0282. (PMID: 33274340) Gastroenterol Rep (Oxf). 2019 Feb;7(1):13-23. (PMID: 30792862) Crit Care Med. 2018 Sep;46(9):e825-e873. (PMID: 30113379) Pharmacotherapy. 2005 Oct;25(10):1348-52. (PMID: 16185179) Sci Rep. 2024 Mar 16;14(1):6355. (PMID: 38491009) |
| Grant Information: | Mayo Midwest Pharmacy Research Committee |
| Contributed Indexing: | Keywords: acute pancreatitis; clevidipine; hypertriglyceridemia; lipid emulsion; propofol; risk factors |
| Substance Nomenclature: | YI7VU623SF (Propofol) 19O2GP3B7Q (clevidipine) 0 (Pyridines) 0 (Triglycerides) |
| Entry Date(s): | Date Created: 20260829 Date Completed: 20260829 Latest Revision: 20260908 |
| Update Code: | 20260909 |
| PubMed Central ID: | PMC13525345 |
| DOI: | 10.1002/phar.70196 |
| PMID: | 42666011 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1875-9114 |
|---|---|
| DOI: | 10.1002/phar.70196 |